Do More With Reuters
Partner Services

Strides Arcolab shares surge on GSK-Aspen deal

Wed Jul 23, 2008 1:40pm IST
 
Email | Print | | Single Page
[-] Text [+]

MUMBAI, July 23 (Reuters) - Shares in Strides Arcolab Ltd (STAR.BO: Quote, Profile, Research) surged 22 percent on Wednesday after a generics drugs deal was struck between GlaxoSmithKline (GSK.L: Quote, Profile, Research) and South Africa's Aspen (APNJ.J: Quote, Profile, Research) involving a joint venture with Strides.

Under the deal, Aspen will license intellectual property and supply finished dosages through Aspen Group companies including Onco Therapies (OTL), an equal joint venture between Strides and Aspen, the South African firm said in a statement.

For detailed story on the GlaxoSmithKline deal with Aspen doubleclick on [ID:nL23881406]

Aspen and OTL will recover intellectual property development costs besides sharing profits with GSK when the drugs are commercialized, the statement added.

The first of the products is expected to be launched in 2010.

The licensing and supply agreement is for 95 emerging markets excluding sub-Saharan Africa and India, Strides Arcolab said in a separate statement.

Strides shares are trading 18 percent higher at 173.50 rupees in a firm Mumbai market. (Reporting by Bharghavi Nagaraju; editing by Rosemary Arackaparambil)

Russian Finance Minister Alexey Kudrin poses with his G20 colleagues and central bank leaders during the family photo at the G20 Finance Ministers meeting at a hotel in St. Andrews, Scotland. REUTERS/POOL New
Pledge to support economies

G20 financial leaders pledged to prepare strategies to end emergency support for their economies, but to keep the aid flowing until recovery was assured.  Full Article | Related Story 

special coverage

Photo
Central Banks Cautious

Reuters tracks the policies of the world's top central banks as the debate over global economic recovery rages on.  Full Coverage 

Market Update

  • IndiaIndia
  • USUS
  • UKUK
  • Asia
  • Most Actives

SHOWCASE

Sanjay Sinha
Balancing Act

In India, it is a tough choice between growth, managing inflation and financial stability.  Full Article 

 
Nipun Mehta
Road to Recovery

There needs to be an acceptable balance created between education and healthcare and infrastructure spend, says Nipun Mehta of SG Private Banking.   Full Article 

 
Robot Asimo

Snapshots of Honda Motor's humanoid robot Asimo  Slideshow 

 
Marketing Strategy
Marketing Strategy

Companies are now using direct marketing methods to sell their products.  Full Article 

 
Exit Plans
Exit Plans

Factbox - Stimulus exit plans for Asia-Pacific's big 5 economies  Full Article